Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies

NCT02626065 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

BIOLOGICAL: blood sampling
DRUG: Nivolumab

Sponsor

Hospices Civils de Lyon